{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:51:48Z","timestamp":1791157908745,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK118240"],"award-info":[{"award-number":["R01 DK118240"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL140934"],"award-info":[{"award-number":["R01 HL140934"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL178501"],"award-info":[{"award-number":["R01 HL178501"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R25 HL156002R25"],"award-info":[{"award-number":["R25 HL156002R25"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["P01 HL164319"],"award-info":[{"award-number":["P01 HL164319"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR085078"],"award-info":[{"award-number":["R01 AR085078"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77372-9","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:48:00Z","timestamp":1788450480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structural basis for rosuvastatin-induced activation of skeletal muscle ryanodine receptor 1"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1836-4316","authenticated-orcid":false,"given":"Gunnar","family":"Weninger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Reiken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8851-4863","authenticated-orcid":false,"given":"Marco C.","family":"Miotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4273-2595","authenticated-orcid":false,"given":"Alexander","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8343-4431","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-2596","authenticated-orcid":false,"given":"Anetta","family":"Wronska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9533-7367","authenticated-orcid":false,"given":"Haikel","family":"Dridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4316-5775","authenticated-orcid":false,"given":"Andrew R.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"77372_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/2047487314550804","volume":"23","author":"J Auer","year":"2016","unstructured":"Auer, J., Sinzinger, H., Franklin, B. & Berent, R. Muscle- and skeletal-related side-effects of statins: tip of the iceberg? Eur. J. Prev. Cardiol. 23, 88\u2013110 (2016).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"77372_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15337","volume":"27","author":"M Shah","year":"2024","unstructured":"Shah, M. et al. Statin-associated muscle symptoms: a comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies. Int. J. Rheum. Dis. 27, e15337 (2024).","journal-title":"Int. J. Rheum. Dis."},{"key":"77372_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","volume":"5","author":"C Stancu","year":"2001","unstructured":"Stancu, C. & Sima, A. Statins: mechanism of action and effects. J. Cell. Mol. Med. 5, 378\u2013387 (2001).","journal-title":"J. Cell. Mol. Med."},{"key":"77372_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11883-024-01246-y","volume":"27","author":"KC Maki","year":"2024","unstructured":"Maki, K. C., Kirkpatrick, C. F., Cheeley, M. K. & Jacobson, T. A. Statin-associated muscle symptoms: identification and recommendations for management. Curr. Atheroscler. Rep. 27, 5 (2024).","journal-title":"Curr. Atheroscler. Rep."},{"key":"77372_CR5","doi-asserted-by":"publisher","first-page":"n135","DOI":"10.1136\/bmj.n135","volume":"372","author":"E Herrett","year":"2021","unstructured":"Herrett, E. et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ 372, n135 (2021).","journal-title":"BMJ"},{"key":"77372_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","volume":"17","author":"BA Warden","year":"2023","unstructured":"Warden, B. A. et al. Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association. J. Clin. Lipidol. 17, 19\u201339 (2023).","journal-title":"J. Clin. Lipidol."},{"key":"77372_CR7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","volume":"400","author":"C Reith","year":"2022","unstructured":"Reith, C. et al. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet 400, 832\u2013845 (2022).","journal-title":"Lancet"},{"key":"77372_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jsps.2023.04.002","volume":"31","author":"A Matyori","year":"2023","unstructured":"Matyori, A., Brown, C. P., Ali, A. & Sherbeny, F. Statins utilization trends and expenditures in the U.S. before and after the implementation of the 2013 ACC\/AHA guidelines. Saudi Pharm. J. 31, 795\u2013800 (2023).","journal-title":"Saudi Pharm. J."},{"key":"77372_CR9","doi-asserted-by":"publisher","first-page":"e061350","DOI":"10.1136\/bmjopen-2022-061350","volume":"12","author":"JS Guadamuz","year":"2022","unstructured":"Guadamuz, J. S., Shooshtari, A. & Qato, D. M. Global, regional and national trends in statin utilisation in high-income and low\/middle-income countries, 2015\u20132020. BMJ Open 12, e061350 (2022).","journal-title":"BMJ Open"},{"key":"77372_CR10","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1111\/bph.15893","volume":"179","author":"C Lindsay","year":"2022","unstructured":"Lindsay, C., Musgaard, M., Russell, A. J. & Sitsapesan, R. Statin activation of skeletal ryanodine receptors (RyR1) is a class effect but separable from HMG-CoA reductase inhibition. Br. J. Pharmacol. 179, 4941\u20134957 (2022).","journal-title":"Br. J. Pharmacol."},{"key":"77372_CR11","doi-asserted-by":"crossref","unstructured":"Marks, A. R. Targeting ryanodine receptors to treat human diseases. J. Clin. Investig. 133, e162891 (2023).","DOI":"10.1172\/JCI162891"},{"key":"77372_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1152\/japplphysiol.01003.2020","volume":"131","author":"M Haseeb","year":"2021","unstructured":"Haseeb, M. & Thompson, P. D. The effect of statins on RyR and RyR-associated disease. J. Appl. Physiol. 131, 661\u2013671 (2021).","journal-title":"J. Appl. Physiol."},{"key":"77372_CR13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00401-020-02150-w","volume":"139","author":"A Kushnir","year":"2020","unstructured":"Kushnir, A. et al. Intracellular calcium leak as a therapeutic target for RYR1-related myopathies. Acta Neuropathol. 139, 1089\u20131104 (2020).","journal-title":"Acta Neuropathol."},{"key":"77372_CR14","doi-asserted-by":"crossref","unstructured":"Weninger, G. et al. Structural basis for simvastatin-induced skeletal muscle weakness associated with type 1 ryanodine receptor T4709M mutation. J. Clin. Investig. 135, e194490 (2025).","DOI":"10.1172\/JCI194490"},{"key":"77372_CR15","doi-asserted-by":"publisher","unstructured":"Molinarolo, S., Valdivia, C. R., Valdivia, H. H. & Van Petegem, F. Cryo-electron microscopy reveals sequential binding and activation of Ryanodine Receptors by statin triplets. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-025-66522-0 (2025).","DOI":"10.1038\/s41467-025-66522-0"},{"key":"77372_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cell.2016.08.075","volume":"167","author":"A des Georges","year":"2016","unstructured":"des Georges, A. et al. Structural basis for gating and activation of RyR1. Cell 167, 145\u2013157.e17 (2016).","journal-title":"Cell"},{"key":"77372_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57074-4","volume":"16","author":"R Wei","year":"2025","unstructured":"Wei, R. et al. Structural insights into transmembrane helix S0 facilitated RyR1 channel gating by Ca2+\/ATP. Nat. Commun. 16, 1936 (2025).","journal-title":"Nat. Commun."},{"key":"77372_CR18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2400497121","volume":"121","author":"G Weninger","year":"2024","unstructured":"Weninger, G. et al. Structural insights into the regulation of RyR1 by S100A1. Proc. Natl. Acad. Sci. USA 121, e2400497121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77372_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.str.2021.08.001","volume":"30","author":"Z Melville","year":"2022","unstructured":"Melville, Z., Kim, K., Clarke, O. B. & Marks, A. R. High-resolution structure of the membrane-embedded skeletal muscle ryanodine receptor. Structure 30, 172\u2013180 e3 (2022).","journal-title":"Structure"},{"key":"77372_CR20","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.str.2022.04.010","volume":"30","author":"Z Melville","year":"2022","unstructured":"Melville, Z. et al. A drug and ATP binding site in type 1 ryanodine receptor. Structure 30, 1025\u20131034 e4 (2022).","journal-title":"Structure"},{"key":"77372_CR21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2422082122","volume":"122","author":"MC Miotto","year":"2025","unstructured":"Miotto, M. C. et al. Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders. Proc. Natl. Acad. Sci. USA 122, e2422082122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77372_CR22","doi-asserted-by":"publisher","first-page":"16725","DOI":"10.1073\/pnas.012688999","volume":"99","author":"GG Du","year":"2002","unstructured":"Du, G. G., Sandhu, B., Khanna, V. K., Guo, X. H. & MacLennan, D. H. Topology of the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum (RyR1). Proc. Natl. Acad. Sci. USA 99, 16725\u201316730 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77372_CR23","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s12276-020-00535-1","volume":"52","author":"JS Woo","year":"2020","unstructured":"Woo, J. S., Jeong, S. Y., Park, J. H., Choi, J. H. & Lee, E. H. Calsequestrin: a well-known but curious protein in skeletal muscle. Exp. Mol. Med. 52, 1908\u20131925 (2020).","journal-title":"Exp. Mol. Med."},{"key":"77372_CR24","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1152\/physrev.00024.2021","volume":"102","author":"SE Lehnart","year":"2022","unstructured":"Lehnart, S. E. & Wehrens, X. H. T. The role of junctophilin proteins in cellular function. Physiol. Rev. 102, 1211\u20131261 (2022).","journal-title":"Physiol. Rev."},{"key":"77372_CR25","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1059344","volume":"292","author":"ES Istvan","year":"2001","unstructured":"Istvan, E. S. & Deisenhofer, J. Structural Mechanism for Statin Inhibition of HMG-CoA Reductase. Science 292, 1160\u20131164 (2001).","journal-title":"Science"},{"key":"77372_CR26","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2217\/pgs.09.85","volume":"10","author":"JE Keskitalo","year":"2009","unstructured":"Keskitalo, J. E., Pasanen, M. K., Neuvonen, P. J. & Niemi, M. Different effects of the ABCG2 C.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10, 1617\u20131624 (2009).","journal-title":"Pharmacogenomics"},{"key":"77372_CR27","first-page":"616","volume":"40","author":"RH Stern","year":"2000","unstructured":"Stern, R. H. et al. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J. Clin. Pharmacol. 40, 616\u2013623 (2000).","journal-title":"J. Clin. Pharmacol."},{"key":"77372_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","volume":"106","author":"MJ Knauer","year":"2010","unstructured":"Knauer, M. J. et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ. Res. 106, 297\u2013306 (2010).","journal-title":"Circ. Res."},{"key":"77372_CR29","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/psp4.13139","volume":"13","author":"L Prieto Garcia","year":"2024","unstructured":"Prieto Garcia, L. et al. Physiologically based pharmacokinetics modeling and transporter proteomics to predict systemic and local liver and muscle disposition of statins. CPT Pharmacomet. Syst. Pharmacol. 13, 1029\u20131043 (2024).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"77372_CR30","doi-asserted-by":"publisher","first-page":"8745","DOI":"10.3390\/ijms21228745","volume":"21","author":"C Murphy","year":"2020","unstructured":"Murphy, C., Deplazes, E., Cranfield, C. G. & Garcia, A. The role of structure and biophysical properties in the pleiotropic effects of statins. Int. J. Mol. Sci. 21, 8745 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"77372_CR31","doi-asserted-by":"publisher","first-page":"107912","DOI":"10.1016\/j.phrs.2025.107912","volume":"220","author":"S Karthikeyan","year":"2025","unstructured":"Karthikeyan, S. et al. Statin drugs and lipid modulation: mechanistic basis considering lipid rafts, kinase signaling, myopathy, and cancer. Pharmacol. Res. 220, 107912 (2025).","journal-title":"Pharmacol. Res."},{"key":"77372_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.toxlet.2016.10.017","volume":"265","author":"SO El-Ganainy","year":"2017","unstructured":"El-Ganainy, S. O. et al. Rosuvastatin safety: an experimental study of myotoxic effects and mitochondrial alterations in rats. Toxicol. Lett. 265, 23\u201329 (2017).","journal-title":"Toxicol. Lett."},{"key":"77372_CR33","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s11606-021-06651-6","volume":"36","author":"AM Mueller","year":"2021","unstructured":"Mueller, A. M. et al. The risk of muscular events among new users of hydrophilic and lipophilic statins: an observational cohort study. J. Gen. Intern. Med. 36, 2639\u20132647 (2021).","journal-title":"J. Gen. Intern. Med."},{"key":"77372_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.phrs.2017.09.013","volume":"128","author":"JC Irwin","year":"2018","unstructured":"Irwin, J. C., Khalesi, S., Fenning, A. S. & Vella, R. K. The effect of lipophilicity and dose on the frequency of statin-associated muscle symptoms: a systematic review and meta-analysis. Pharm. Res. 128, 264\u2013273 (2018).","journal-title":"Pharm. Res."},{"key":"77372_CR35","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Byty\u00e7i","year":"2022","unstructured":"Byty\u00e7i, I. et al. Prevalence of statin intolerance: a meta-analysis. Eur. Heart J. 43, 3213\u20133223 (2022).","journal-title":"Eur. Heart J."},{"key":"77372_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/2044-5040-3-22","volume":"3","author":"M Knoblauch","year":"2013","unstructured":"Knoblauch, M., Dagnino-Acosta, A. & Hamilton, S. L. Mice with RyR1 mutation (Y524S) undergo hypermetabolic response to simvastatin. Skelet. Muscle 3, 22 (2013).","journal-title":"Skelet. Muscle"},{"key":"77372_CR37","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"77372_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"TD Goddard","year":"2018","unstructured":"Goddard, T. D. et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci. 27, 14\u201325 (2018).","journal-title":"Protein Sci."},{"key":"77372_CR39","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nature09471","volume":"468","author":"CC Tung","year":"2010","unstructured":"Tung, C. C., Lobo, P. A., Kimlicka, L. & Van Petegem, F. The amino-terminal disease hotspot of ryanodine receptors forms a cytoplasmic vestibule. Nature 468, 585\u2013588 (2010).","journal-title":"Nature"},{"key":"77372_CR40","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"77372_CR41","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"77372_CR42","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/S0006-3495(93)81293-1","volume":"65","author":"OS Smart","year":"1993","unstructured":"Smart, O. S., Goodfellow, J. M. & Wallace, B. A. The pore dimensions of gramicidin A. Biophys. J. 65, 2455\u20132460 (1993).","journal-title":"Biophys. J."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77372-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77372-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77372-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:09:27Z","timestamp":1791155367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77372-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77372"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77372-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.R.M. owns stock in RyCarma Therapeutics Inc., a company developing compounds targeting RyR. A.R.M. is coinventor on US patent nos. US8022058 and US8710045. G.W., H.D., M.C.M., and A.R.M. are inventors on the patent application entitled \u201cStatin Innovation for Muscle-Friendly Cholesterol Management\u201d (Invention Report CU24350) to be filed by Columbia University. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10487"}}